and Clostridium piliforme in mice, 4 which were not dangerous for humans, but were detrimental to research because of unanticipated loss of animals. Also in the early 20th century, it became evident that animals could be rendered free of all microbial organisms (germ-free, axenic) without fatal consequences if maintained in closed isolators. 5, 6 In 1947, Henry Foster founded the United States breeding company later known as Charles River. With the concurrent introduction of the 3Rs (refinement, reduction, replacement) 7 to animal-based research, he started the use of cesarean section and barrier protection as a way to refine rodent models by producing them free of well-defined specific pathogens. 8 Disease-provoking rodent infections were all eliminated, while new ones, such as Citrobacter rodentium 9 and Filobacterium rodentium (cilia-associated respiratory bacillus) 10 were described and subsequently also fully eliminated. [11] [12] [13] Nowadays laboratory rodents are produced only behind barriers subjected to thorough health monitoring programs and, should any of the previously experienced bacterial agents be found, depopulation is often the only viable solution.
Early attempts to move rederived germ-free rodents from isolators to barrier-protected facilities were often confounded by opportunistic infections. To circumvent this, Russell W. Schaedler explored whether limiting the number of commensal bacterial species could minimize clinical disease in reconstituted rodents.
14 He selected known commensal (i.e. not associated with disease) bacteria, which could be cultivated, and this collection became known as the Schaedler flora. 15 After a redesign it became ''The altered Schaedler flora'' (ASF), 16 which today is the initial microbiota of most commercial laboratory rodent-breeding colonies. ASF bacteria can be recovered from rodents several years after the initial colonization. 17, 18 Although ASF provides a valuable tool for controlled studies of the role of microbes in models of disease, the translatability of such studies must be viewed with caution as ASF does not recapitulate the complexity of microbiota that exist in human populations. As a result, we must interpret such studies in combination with studies performed in rodents with complex microbiota. 19 However, the latter are also potentially flawed as during 70 years of rederivation and barrier protection key microorganisms crucial to the function of the animals as models for human beings may have been lost, or at least found in only some rodent colonies. An example can be found with the anti-inflammatory bacterium Akkermansia muciniphila, 20 whose presence in contemporary rodent colonies is now inconsistent and thus may be affecting reproducibility of inflammatory models of disease. This phenomenon is also well known in human medicine, in which it has been hypothesized that the ''loss of old friends'' has affected the incidence of a number of diseases, such as allergies and type 1 diabetes. 21 To address this there is growing interest in using pet store or wild mice, which possess microbiota that have evolved in a more complex and antigen-experienced environment. While such studies may have merit, they are also complicated by lack of controlled microbiota and adventitious pathogens that most research facilities strive to exclude. 22 A happy medium must be found that results in translatable microbiota complexity in a controlled and interpretable setting. The 10th Federation for Laboratory Animal Science Associations (FELASA) symposium in 2007 was the first FELASA symposium at which this question was raised in one talk. 23 At the 2010 FELASA symposium, there were five oral presentations on the impact of the microbiota on laboratory rodents, 24 and at the FELASA symposium in 2013 this further increased. 25 In the same period, there was a general transition in bacteriology from applying cultivation as the method for screening and characterization of microbes to the application of sequence-based methods. These began with polymerase chain reaction-based methods and have evolved to targeted generic 16S sequencing to fully metagenomic sequencing. This has brought microbiological characterization from being able to identify 15% to 20% of the members of a microbiota to being able to describe close to 100%. Moreover, we are now able to describe not only the microbial phylogeny but also the full functional capacity of the microbiota. During the last decade, the costs of these procedures have declined from being unreachable for routine purposes to being very amenable to routine use.
The emergence of next-generation sequencing tools has led to a change in terminology and our understanding of microbiota. Previously, we might vaguely describe normal flora, but this can now be referred to as microbiota, which describes the complex community of all microorganisms in the sample. With metagenomics we also now have a better understanding of the microbiome, the massive collection of functional genes. The latter represent more than one million genes expressed by microbiota that far outweigh the approximately 23,000 genes expressed by the mammalian host. This growing characterization and understanding of the complex microbiota has also led to a new paradigm in which in addition to considering genetics as a basis for phenotype we must also consider the influence of differing microbiota on said phenotypes. 26 It is still premature to say where this development will take us. Perhaps we will begin to routinely survey the microbiome of our research subjects and even provide certificates akin to health certificates. Perhaps animals with specified microbiotas will be requested. It is also likely that, like inbred strains, not all microbiotas will be equally beneficial for all studies. If so, perhaps producers will offer to supply the same strain with different microbiotas. Routine microbiota characterization would also benefit individual studies so interindividual variation could be considered in sample size calculations. Regardless, we have an obligation to incorporate anything that can improve science and animal welfare. The editors hope this special issue of Laboratory Animals will provide the reader contemporary information about this exciting field, where it has taken animal research today, and where it may go in the future.
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